We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
Read MoreHide Full Article
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that the FDA has accepted the new drug application for its lead pipeline candidate, mitapivat, for priority review. The NDA is seeking the approval of the candidate as a potential treatment of adult patients with pyruvate kinase (“PK”) deficiency, a rare, inherited disease. Currently, there is no treatment approved for the given indication.
The priority review has reduced the anticipated timeline for review of mitapivat NDA from 10 months to six months. The FDA will announce its decision onthepotential approval for mitapivat by Feb 17, 2022.
Shares of Agios were up nearly 3% during after-hours trading on Aug 17 with the FDA granting priority review tag to the NDA. The company’s shares have gained 3.1% so far this year compared with the industry’s increase of 3.6%.
Image Source: Zacks Investment Research
The NDA was based on data from two pivotal phase III studies – ACTIVATE and ACTIVATE-T – which evaluated mitapivat for treating PK deficiency in adults who are not regularly transfused and those who are regularly transfused, respectively.
A marketing authorization application, seeking approval of mitapivat for treating adults with PK deficiency in Europe,is also under review.
Upon potential approval and launch, mitapivat can provide a first potentially disease-modifying therapy for people with PK deficiency, thereby serving an area of high unmet medical need. However, the company’s operating expenses will likely go higher in the upcoming quarters to support pre-commercialization and commercialization activities for mitapivat. Moreover, the company is also conducting several clinical studies to support the approval of mitapivat in other hemolytic anemias indications.
A phase II/III study on mitapivat for sickle cell disease is expected to begin by year-end. The company also plans to initiate two phase III studies on mitapivat in thalassemia (regularly transfused as well as not regularly transfused) this year.
We remind investors that Agios completed the sale of its oncology portfolio to France-based pharmaceutical company, Servier, in March 2021. Following this sale, the company’s sole focus now remains on expanding its genetically defined disease portfolio, including the clinical development of mitapivat.
This apart, Agios is also evaluating AG-946, its next-generation pyruvate kinase-R activator, in a phase I study for the treatment of hemolytic anemia.
Some better-ranked stocks from the biotech/drug sector include Horizon Therapeutics , Repligen Corporation (RGEN - Free Report) and Aptose Biosciences (APTO - Free Report) . While Horizon sports a Zacks Rank #1 (Strong Buy), Repligen and Aptose currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon’s earnings per share estimates for 2021 have increased from $3.62 to $4.46 in the past 30 days while that for 2022 have increased from $5.18 to $5.84 over the same period. The stock has risen 44.2% in the year so far.
Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 30 days while that for 2022 have increased from $2.56 to $3.02 over the same period. The stock has risen 34.1% in the year so far.
Aptose’s loss per share estimates for 2021 have narrowed from 76 cents to 68 cents in the past 30 days while that for 2022 have narrowed from 96 cents to 92 cents over the same period.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that the FDA has accepted the new drug application for its lead pipeline candidate, mitapivat, for priority review. The NDA is seeking the approval of the candidate as a potential treatment of adult patients with pyruvate kinase (“PK”) deficiency, a rare, inherited disease. Currently, there is no treatment approved for the given indication.
The priority review has reduced the anticipated timeline for review of mitapivat NDA from 10 months to six months. The FDA will announce its decision onthepotential approval for mitapivat by Feb 17, 2022.
Shares of Agios were up nearly 3% during after-hours trading on Aug 17 with the FDA granting priority review tag to the NDA. The company’s shares have gained 3.1% so far this year compared with the industry’s increase of 3.6%.
Image Source: Zacks Investment Research
The NDA was based on data from two pivotal phase III studies – ACTIVATE and ACTIVATE-T – which evaluated mitapivat for treating PK deficiency in adults who are not regularly transfused and those who are regularly transfused, respectively.
A marketing authorization application, seeking approval of mitapivat for treating adults with PK deficiency in Europe,is also under review.
Upon potential approval and launch, mitapivat can provide a first potentially disease-modifying therapy for people with PK deficiency, thereby serving an area of high unmet medical need. However, the company’s operating expenses will likely go higher in the upcoming quarters to support pre-commercialization and commercialization activities for mitapivat. Moreover, the company is also conducting several clinical studies to support the approval of mitapivat in other hemolytic anemias indications.
A phase II/III study on mitapivat for sickle cell disease is expected to begin by year-end. The company also plans to initiate two phase III studies on mitapivat in thalassemia (regularly transfused as well as not regularly transfused) this year.
We remind investors that Agios completed the sale of its oncology portfolio to France-based pharmaceutical company, Servier, in March 2021. Following this sale, the company’s sole focus now remains on expanding its genetically defined disease portfolio, including the clinical development of mitapivat.
This apart, Agios is also evaluating AG-946, its next-generation pyruvate kinase-R activator, in a phase I study for the treatment of hemolytic anemia.
Agios Pharmaceuticals, Inc. Price
Agios Pharmaceuticals, Inc. price | Agios Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Agios has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech/drug sector include Horizon Therapeutics , Repligen Corporation (RGEN - Free Report) and Aptose Biosciences (APTO - Free Report) . While Horizon sports a Zacks Rank #1 (Strong Buy), Repligen and Aptose currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon’s earnings per share estimates for 2021 have increased from $3.62 to $4.46 in the past 30 days while that for 2022 have increased from $5.18 to $5.84 over the same period. The stock has risen 44.2% in the year so far.
Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 30 days while that for 2022 have increased from $2.56 to $3.02 over the same period. The stock has risen 34.1% in the year so far.
Aptose’s loss per share estimates for 2021 have narrowed from 76 cents to 68 cents in the past 30 days while that for 2022 have narrowed from 96 cents to 92 cents over the same period.